| scholarly article | Q13442814 |
| P50 | author | Denis Glotz | Q56859181 |
| P2093 | author name string | D Charron | |
| C Lefaucheur | |||
| D Nochy | |||
| G S Hill | |||
| C Gautreau | |||
| C Suberbielle-Boissel | |||
| J Andrade | |||
| J Verine | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 1099-1107 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection | |
| P478 | volume | 9 |
| Q35008036 | A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation |
| Q90198666 | A potential role of neutrophil extracellular traps (NETs) in kidney acute antibody mediated rejection |
| Q39130806 | A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. |
| Q40331013 | AST Cutting Edge of Transplantation 2013 Meeting Report: a comprehensive look at B cells and antibodies in transplantation |
| Q41118002 | Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management |
| Q38215262 | Acute and chronic antibody-mediated rejection in pediatric kidney transplantation |
| Q39105369 | Acute antibody-mediated rejection in kidney transplant recipients |
| Q37425991 | Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient |
| Q37676032 | Advances in diagnosing and managing antibody-mediated rejection |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q40180170 | Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease. |
| Q36296061 | Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. |
| Q37698860 | Antibody-Mediated Rejection: A Review |
| Q37990988 | Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale |
| Q35915453 | Antibody-mediated rejection in kidney transplantation: a review |
| Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
| Q37835834 | Antibody-mediated rejection in kidney transplantation: an update |
| Q47773036 | Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q38062614 | Antibody-mediated vascular rejection of kidney allografts: a population-based study |
| Q38082735 | Apheresis therapy in children: an overview of key technical aspects and a review of experience in pediatric renal disease |
| Q37058043 | Banff 2011 Meeting report: new concepts in antibody-mediated rejection |
| Q37820338 | Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach |
| Q38282840 | Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection |
| Q34189435 | Bortezomib in kidney transplantation |
| Q33584895 | Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial |
| Q38977574 | Cell-mediated and humoral acute vascular rejection and graft loss: A registry study. |
| Q39009557 | Chronic allograft injury: Mechanisms and potential treatment targets |
| Q37827197 | Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients |
| Q33412327 | Clinical aspects: focusing on key unique organ-specific issues of renal transplantation |
| Q38163419 | Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis |
| Q93188012 | Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients |
| Q39716270 | Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. |
| Q88643834 | Complications of therapeutic apheresis in pediatric kidney transplantation |
| Q36752176 | Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection |
| Q26829789 | Current state of renal transplant immunosuppression: Present and future |
| Q38168293 | Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q40815282 | Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations |
| Q30279164 | Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells |
| Q42111937 | Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. |
| Q47286616 | Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. |
| Q27027082 | Effector mechanisms of rejection |
| Q85304336 | Efficacy and safety of plasma exchange: ann 11-year single-center experience of 2730 procedures in 317 patients |
| Q37960177 | Emerging drugs for the treatment of transplant rejection |
| Q89746966 | Evaluation and Treatment of Acute Rejection in Kidney Allografts |
| Q54559091 | Expression patterns of CD56+ and CD16+ cells in renal transplant biopsies with acute rejection: Associations with microcirculation injuries and graft survival. |
| Q50852390 | Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient. |
| Q27026499 | Flow cytometry and solid organ transplantation: a perfect match |
| Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
| Q34122035 | Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis |
| Q38967641 | Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study |
| Q36612789 | Human leukocyte antigen antibody incompatible renal transplantation |
| Q34484801 | Immunosuppressive Medications |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q39708039 | Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion |
| Q94355534 | Interventions for treating antibody‐mediated acute rejection in kidney transplant recipients |
| Q35808401 | Intravenous immunoglobulin for antibody-mediated keratolimbal allograft rejection |
| Q41834576 | Late kidney dysfunction in a kidney transplant recipient |
| Q44722151 | Low- versus high-dose rituximab for antibody-mediated rejection after kidney transplantation |
| Q45821566 | Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection. |
| Q37898509 | New therapeutic approaches to antibody-mediated rejection in renal transplantation |
| Q38021735 | Nonsurgical care of intestinal and multivisceral transplant recipients: a review for the intensivist |
| Q36865787 | Novel functions of B cells in transplantation |
| Q38176005 | Novel immunosuppressive agents in kidney transplantation |
| Q104063169 | Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice |
| Q34124202 | Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation |
| Q36173541 | Rational clinical trial design for antibody mediated renal allograft injury. |
| Q35659332 | Recent advances in renal transplantation: antibody-mediated rejection takes center stage |
| Q42343473 | Renal association clinical practice guideline in post-operative care in the kidney transplant recipient |
| Q39485911 | Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study |
| Q64235794 | Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression |
| Q52656964 | Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation. |
| Q40461706 | Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection. |
| Q27026434 | Rituximab in renal transplantation |
| Q37241071 | Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience |
| Q34222399 | Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies |
| Q35790552 | Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts |
| Q102319267 | Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI) |
| Q42598786 | Summary of FDA antibody-mediated rejection workshop |
| Q38877375 | The importance of non-HLA antibodies in transplantation |
| Q84289057 | The role of splenectomy in the setting of refractory humoral rejection after kidney transplantation |
| Q37992871 | The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection |
| Q37690953 | The yin and yang of B cells in graft rejection and tolerance |
| Q37978684 | Therapeutic apheresis in children: special considerations |
| Q30456482 | Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine |
| Q30458220 | Therapeutic apheresis in renal transplantation; current practices |
| Q91991945 | Therapeutic plasma exchange - A brief review of indications, urgency, schedule, and technical aspects |
| Q38118112 | Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. |
| Q91520925 | Therapeutic plasma exchange: Review of current indications |
| Q38205229 | Transplant glomerulopathy: the interaction of HLA antibodies and endothelium |
| Q38017160 | Transplant immunology for non-immunologist |
| Q33803804 | Transplantation immunology: solid organ and bone marrow |
| Q41967328 | Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step |
| Q36238896 | Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports |
| Q27021397 | Treatment options and strategies for antibody mediated rejection after renal transplantation |
| Q102319264 | Urgent therapeutic plasma exchange |
| Q38769922 | Use of polyclonal/monoclonal antibody therapies in transplantation |
| Q35790601 | Utility of HLA Antibody Testing in Kidney Transplantation |
Search more.